Nomenclature and systems of classification for cardiomyopathy in children

Laura Konta1, Rodney C G Franklin2, Juan P Kaski1

  • 11Inherited Cardiovascular Diseases Unit,Great Ormond Street Hospital,London,United Kingdom.

Cardiology in the Young
|September 18, 2015
PubMed

Insights

Cardiomyopathy classification has evolved with genetics and imaging, leading to distinct systems like AHA and ESC. Harmonization efforts aim to unify these complex diagnostic approaches for better patient care.

Area of Science:

  • Cardiology
  • Genetics
  • Medical Classification Systems

Background:

  • Cardiomyopathy classification has evolved significantly since the 1960s, driven by advancements in imaging, disease recognition, and genetic understanding.
  • Early classifications focused on pathophysiological types (dilated, hypertrophic, restrictive, arrhythmogenic), later subdivided into idiopathic and disease-specific categories.
  • Genetic discoveries increasingly link idiopathic cardiomyopathies to specific mutations, though genotype-phenotype correlations remain complex due to variable penetrance and age-dependent factors.

Purpose of the Study:

  • To review the evolution of cardiomyopathy classification systems.
  • To compare the dominant American Heart Association (AHA) and European Society of Cardiology (ESC) classification approaches.
  • To discuss the challenges and recent attempts at harmonizing these systems.

Main Methods:

  • Review of historical and current literature on cardiomyopathy classification.
  • Analysis of the key features and differences between the AHA (2006) and ESC (2008) systems.
  • Examination of the impact of genetic advances on classification.

Main Results:

  • Two major classification systems, AHA and ESC, currently dominate, each with distinct criteria and subdivisions.
  • The AHA system categorizes cardiomyopathies as primary (heart-focused, genetic) or secondary (systemic involvement).
  • The ESC system differentiates between familial and non-familial types, excluding ion channelopathies and focusing on specific disease subtypes.

Conclusions:

  • Despite differing approaches, clinical evaluation, diagnostic imaging, and genetic testing are crucial for diagnosing cardiomyopathy.
  • The MOGE(S) system represents a recent attempt to harmonize existing classifications but requires further validation.
  • The ongoing evolution of classification reflects the complexity of cardiomyopathies and the need for integrated diagnostic strategies.

Related Concept Videos

Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
818
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
718
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
603
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
647
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
769
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
830